MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)
Stock · NASDAQ · Health Care
$9.55as of 10/16/2026
Price chart
Active signals
MLTX Signal Track Record
How signals performed across all stocks →What MLTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -2.9% | 39% | October 8, 2026 |
| Bollinger Band Breakout | 23 | -1.3% | 39% | June 22, 2026 |
| Bollinger Band Breakdown | 17 | +14.6% | 76% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +2.0% | 53% | August 13, 2026 |
| Any 20-session window (baseline) | +2.2% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 130
- Website
- moonlaketx.com/
Fundamentals
- 1-day range
- $10.48$10.84
- Market cap
- $1.33B
- P/E (trailing)
- —
- P/E (forward)
- -3.16
- EPS (trailing)
- $-3.83
- Dividend yield
- —
- Beta
- 1.12
- Avg. volume
- 1.47M
Forecasts
13 analyst ratings
MoonLake Immunotherapeutics Class A Ordinary Shares Competitors
Chosen by industry and closest market cap.
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Kristian Reich · July 27, 2026 · Sale1.1K @ $20
- Kristian Reich · July 22, 2026 · Sale2.4K @ $20
- Kristian Reich · July 21, 2026 · Sale50.0K @ $20.02
- Kristian Reich · July 20, 2026 · Sale43.7K @ $20.09
- Kristian Reich · July 15, 2026 · Sale16.1K @ $20.01
- da Silva Jorge Santos · July 10, 2026 · Sale68.3K @ $20.02
- da Silva Jorge Santos · July 9, 2026 · Sale33.9K @ $20.01
- da Silva Jorge Santos · July 1, 2026 · Sale47.8K @ $20.03
- Matthias Bodenstedt · June 22, 2026 · Sale39.1K @ $22.04
- BIOTECHNOLOGY VALUE FUND L P · June 17, 2026 · Grant22.2K
- Matthias Bodenstedt · May 11, 2026 · Sale13.7K @ $20.02
- Matthias Bodenstedt · April 14, 2026 · Sale2.4K @ $19.56
- da Silva Jorge Santos · April 13, 2026 · Sale51.9K @ $18.23
Institutional Ownership
March 31, 2026
- Total shares held
- 63.67M
- Total value held
- $1.15B
- Institutional holders
- 143
- Unknown16.00M
- Unknown6.41M
- Unknown4.48M
- Unknown3.45M
- Unknown2.39M
- Unknown2.08M
- Unknown1.81M
- Unknown1.71M
- Unknown1.50M
- Unknown1.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MLTX noted in psoriatic arthritis market landscape report
A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.
MLTX noted in psoriatic arthritis market landscape report. A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.